Core Insights - NLS Pharmaceutics Ltd. announced positive preclinical results for Mazindol, indicating its potential as a non-opioid treatment for fentanyl use disorder, which is a significant contributor to opioid-related overdose deaths in the U.S. [1][2] Industry Overview - The U.S. opioid and substance use disorder treatment market was valued at over $35 billion in 2021 and is projected to exceed $60 billion by 2029, driven by the urgent demand for safer alternatives to traditional opioid therapies [2]. Study Design and Findings - Study KO-943 utilized a validated conditioned place preference (CPP) paradigm in mice to assess the effects of Mazindol on fentanyl-induced behavior [3]. - Fentanyl significantly increased place preference, confirming its rewarding effect, while Mazindol at 0.5 mg/kg significantly reduced this effect, indicating a dose-dependent response [4]. Mechanism of Action - Mazindol acts as a pan-monoamine reuptake inhibitor with multiple pharmacological effects, including partial mu-opioid receptor modulation, serotonin 5-HT1A receptor interaction, and orexin-2 receptor activity, positioning it as a differentiated alternative to current opioid therapies [6][7]. Strategic Developments - NLS Pharmaceutics recently raised up to $3 million and signed a $25 million equity facility agreement as part of a strategic merger with Kadimastem Ltd., which will support the development of both companies' clinical assets [5][8].
NLS Pharmaceutics Announces Positive Results from Study KO-943 Demonstrating Mazindol Reduces Fentanyl-Induced Reward in Animal Models